Oncologics were the top-selling class of therapeutics last year, with sales of $52.37 billion, followed by lipid regulators and respiratory agents, according to IMS. Autoimmune agents posted the fastest annual growth rate in 2009 among the top 15 therapeutic classes. Sales of autoimmune agents increased 18.0% to $13.75 billion, making them the 11th largest therapeutic […]
Although estimated to be worth $10 billion by 2015, the biosimilars market will be challenging and thus is attracting only large companies and specialist providers. Development of biosimilars takes up to eight years at a cost of $100–$150 million. But prices are only expected to be 20%–30% lower than biologics. Multiple patent challenges are expected […]
The Codex Alimentarius Commission, the United Nation’s food standards body, has announced new food standards. The maximum amount of melamine permitted in powdered infant formula was set at 1 mg/kg and at 2.5 mg/kg for other foods and animal feed. The Codex also set maximum levels for aflatoxins in ready-to-eat Brazil nuts at 10 µg/kg […]
As big oil projects become more complex and riskier, US and European oil companies are entering into deals for gas projects in Australia and America. In America, new shale-gas reserves have triggered a string of asset acquisitions. In contrast to oil, gas development costs have fallen and Western companies’ expertise and capital are in demand […]
The American Chemistry Council expects US chemical production to grow 6.0% this year, driven by the economic recovery and exports, and to rise 4.0% in 2011. Excluding pharmaceuticals, output is forecast to grow 6.8% in 2010. The fastest-growing sector this year will be bulk petrochemicals and organics, with output up 10.7%. Basic chemical production is […]
The US Department of Agriculture (USDA) released a report this month detailing the US’s production and consumption capacities for biofuels. New US Renewable Fuel Standards (RFS2), which take effect July 1, mandate the use of 36 billion gallons of bio-based transportation fuels by 2022. The EPA estimates that 15 billion gallons could come from conventional […]
According to CMR International’s annual yearbook for 2009, pharmaceutical company spending on R&D declined 0.3%, with R&D as a percentage of sales falling to 15%. Compared to the 2004–2006 period, the number of drugs abandoned during Phase III clinical trials nearly doubled in 2007–2009 to 40. For every 12 drugs in preclinical research, two progressed […]
Demand for DNA testing in US crime labs from 2005 to 2008 increased despite federal funding for the DNA Initiative, which is administered by the National Institute of Justice (NIJ). Demand is increasing due to greater awareness, the use of DNA testing in property crimes, advances in DNA science, the reopening of old cases and […]
Rapidly growing US sales of oncology drugs is making the sector a focus of drug development. Approximately 40% of the estimated 40,000 drugs in Phase I, II or III trials are cancer related. US sales of oncology drugs, excluding hormonal therapies and vaccines, increased 10.8% in 2009 to $18.5 billion. US sales of targeted cancer […]
Combined sales for the top 50 US chemical companies declined 21% to $247.5 billion in 2009, reflecting the impact of the recession. Only four firms recorded revenue increases. The companies with the highest sales were Dow Chemical, Exxon Mobil, DuPont and PPG Industries, which recorded 2009 revenue changes of -22.0%, -30.1%, -14.6%, -18.3%, respectively. Sales […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
